Exhibit 99.1

[SOLUTIA logo]
                                                                        News



                                              SOLUTIA INC.
                                              575 Maryville Centre Drive
                                              St. Louis, Missouri 63141

                                              P.O. Box 66760
                                              St. Louis, Missouri 63166-6760

FOR IMMEDIATE RELEASE

----------------------------------------------------------------------------

                                      MEDIA: Dan Jenkins (314) 674-8552
                                      INVESTORS: Tim Spihlman (314) 674-5206


      SOLUTIA MAINTAINS COMMITMENT TO PHARMACEUTICAL SERVICES BUSINESS

COMPANY WILL CONTINUE TO INVEST IN WORLD-CLASS FACILITIES AT CARBOGEN AND AMCIS

ST. LOUIS - APRIL 14, 2005 -- Solutia Inc. (OTCBB: SOLUQ) today announced
that its subsidiary, Solutia Europe SA/NV, has completed a strategic review
of its Pharmaceutical Services business, comprised of CarboGen and AMCIS.
After assessing several alternatives, including a potential sale, Solutia
has decided it will retain this business. Based in Switzerland, CarboGen and
AMCIS (http://www.carbogen-amcis.com) provide seamless drug development and
commercialization services for leading pharmaceutical and biotechnology
companies.

"CarboGen and AMCIS are a small but profitable part of Solutia's portfolio,"
said Jeffry N. Quinn, president and CEO, Solutia Inc. "We have concluded
that we can maximize value for our stakeholders by continuing to own and
operate this business. We will invest as needed in CarboGen and AMCIS to
meet the emerging needs of our customers."

Solutia's recent investments in CarboGen and AMCIS include the December 2004
completion of a state-of-the-art development and manufacturing facility for
highly potent active pharmaceutical ingredients (API). Through this
facility, CarboGen and AMCIS offer the full breadth of capabilities to
deliver highly potent API supply for clinical trials and commercial use,
across all categories of highly potent compounds including oncologics,
cytotoxics and cytostatics. Other recent investments include the addition of
two, 2500-liter reactors at the Bubendorf site in December 2004, as well as
new labs and a pilot plant for the production of highly potent APIs.

CarboGen and AMCIS account for approximately 2 percent of the annual sales
of Solutia Inc. Their world-class research and development facilities are
located at three sites in Switzerland: Aarau, Bubendorf, and Neuland.


Dedicated to reducing the time, cost and risks associated with drug
development, CarboGen and AMCIS focus on supporting the drug substance
development process from bench to market. The business delivers integrated
chemistry services that include process research and API supply as well as
process development and API manufacture for clinical trials and commercial
use.

For more information on CarboGen and AMCIS, visit
http://www.carbogen-amcis.com.

                                   # # #

FORWARD LOOKING STATEMENT
This press release contains forward-looking statements. Forward-looking
statements are subject to known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from the future results, performance or achievements
expressed or implied by the forward looking statements. Assumptions and
other important factors that could cause our actual results to differ
materially from those anticipated in our forward-looking statements include,
among other things: (i) the ability of Solutia to develop, prosecute,
confirm and consummate one or more Chapter 11 plans of reorganization; (ii)
the potential adverse impact of the Chapter 11 filing on Solutia's
operations, management and employees, and the risks associated with
operating businesses under Chapter 11 protection; (iii) the ability of
Solutia to comply with the terms of the DIP financing facility; (iv) world
economic conditions, competitive pressures, gain or loss of significant
customers, labor relations and disruption of operations, raw material and
energy costs, currency and interest rate fluctuations, success in
implementing pricing actions and managing spending, operating rates, cost of
debt, environmental compliance and remediation and other factors; (v)
customer response to the Chapter 11 filing; and (vi) the risk factors or
uncertainties listed from time to time in Solutia's filings with the
Securities and Exchange Commission and with the U.S. Bankruptcy Court in
connection with the Company's Chapter 11 filing. Other factors and
assumptions not identified above are also relevant to the forward-looking
statements, and if they prove incorrect, could also cause actual results to
differ materially from those projected.

CORPORATE PROFILE
Solutia (http://www.Solutia.com) uses world-class skills in applied
chemistry to create value-added solutions for customers, whose products
improve the lives of consumers every day. Solutia is a world leader in
performance films for laminated safety glass and after-market applications;
process development and scale-up services for pharmaceutical fine chemicals;
specialties such as water treatment chemicals, heat transfer fluids and
aviation hydraulic fluid and an integrated family of nylon products
including high-performance polymers and fibers.

Solutia ... Solutions for a Better Life.
SOURCE: SOLUTIA INC.
ST. LOUIS
4/14/05